Corbus Pharmaceuticals (CRBP) News Today $6.03 +0.11 (+1.86%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$5.82 -0.21 (-3.48%) As of 04/17/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period We Think Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Can Afford To Drive Business GrowthApril 18 at 4:24 PM | finance.yahoo.comCorbus Pharmaceuticals management to meet with Piper SandlerApril 17 at 8:30 PM | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Consensus Rating of "Buy" by BrokeragesShares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) have been given a consensus rating of "Buy" by the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation and one has issued a strMarch 30, 2025 | marketbeat.comCorbus announces first patient dosed in Phase 1 CRB-913 studyMarch 28, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of ObesityMarch 28, 2025 | globenewswire.comB. Riley Lifts Earnings Estimates for Corbus PharmaceuticalsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley raised their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel now anticipatesMarch 17, 2025 | marketbeat.comHC Wainwright Issues Positive Estimate for CRBP EarningsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - HC Wainwright upped their Q1 2025 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now forecasts that theMarch 17, 2025 | marketbeat.comWhat is B. Riley's Forecast for CRBP Q1 Earnings?Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at B. Riley issued their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Thursday, March 13th. B. Riley analyst K. Patel anticipates that the biopharmaceutical comMarch 15, 2025 | marketbeat.comWhat is Lifesci Capital's Estimate for CRBP Q1 Earnings?Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at Lifesci Capital boosted their Q1 2025 EPS estimates for Corbus Pharmaceuticals in a research report issued on Tuesday, March 11th. Lifesci Capital analyst M. Belghiti now forecasts that the biopharmaceutical comMarch 15, 2025 | marketbeat.comWedbush Reaffirms Outperform Rating for Corbus Pharmaceuticals (NASDAQ:CRBP)Wedbush reissued an "outperform" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday.March 13, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $50.00 price target (down previously from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday.March 13, 2025 | marketbeat.comCorbus Pharmaceuticals (CRBP) Gets a Buy from RBC CapitalMarch 12, 2025 | markets.businessinsider.comJefferies Financial Group Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00Jefferies Financial Group dropped their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a "buy" rating on the stock in a research report on Tuesday.March 12, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Posts Quarterly Earnings Results, Beats Expectations By $0.24 EPSCorbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping analysts' consensus estimates of ($1.02) by $0.24.March 12, 2025 | marketbeat.comCorbus Pharmaceuticals price target lowered to $53 from $70 at JefferiesMarch 11, 2025 | markets.businessinsider.comCorbus Pharmaceuticals (CRBP) Gets a Buy from William BlairMarch 11, 2025 | markets.businessinsider.comCorbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.comStockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research report on Thursday.March 7, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings Inc. stock rises Wednesday, still underperforms marketMarch 5, 2025 | marketwatch.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Buy" by AnalystsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has received an average recommendation of "Buy" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a buy recommendation and one has given a strong buMarch 4, 2025 | marketbeat.comCorbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on TuesdayCorbus Pharmaceuticals (NASDAQ:CRBP) will be releasing earnings before the market opens on Tuesday, March 11, Financial Modeling Prep reports.March 4, 2025 | marketbeat.comCorbus Pharmaceuticals (NASDAQ:CRBP) Earns Outperform Rating from Analysts at William BlairWilliam Blair began coverage on shares of Corbus Pharmaceuticals in a research note on Friday. They set an "outperform" rating for the company.March 1, 2025 | marketbeat.comCorbus Pharmaceuticals initiated with an Outperform at William BlairFebruary 28, 2025 | markets.businessinsider.comWilliam Blair Initiates Coverage of Corbus Pharmaceuticals Holdings (CRBP) with Outperform RecommendationFebruary 28, 2025 | msn.comCorbus Pharmaceuticals to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | finance.yahoo.comCorbus Pharmaceuticals (NASDAQ:CRBP) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a report on Tuesday.February 19, 2025 | marketbeat.comMizuho Securities Reaffirms Their Buy Rating on Corbus Pharmaceuticals (CRBP)February 16, 2025 | markets.businessinsider.comCorbus Pharmaceuticals announces data from its US, UK study of CRB-701February 14, 2025 | markets.businessinsider.comCorbus Pharmaceuticals falls after trial data for lead assetFebruary 14, 2025 | msn.comRBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)February 14, 2025 | markets.businessinsider.comCRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025February 14, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Corbus Pharmaceuticals (CRBP), Genmab (GMAB) and CVRx (CVRX)February 13, 2025 | markets.businessinsider.comEquities Analysts Set Expectations for CRBP FY2029 EarningsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued to clients and investors on Monday, February 10th. HC Wainwright analyst A.February 12, 2025 | marketbeat.comCorbus presents new cancer drug study at ASCO GUFebruary 12, 2025 | msn.comCRBP stock touches 52-week low at $9.1 amid market challengesFebruary 12, 2025 | msn.comCorbus Pharmaceuticals announces clinical data for CRB-701February 11, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GUFebruary 11, 2025 | globenewswire.comH.C. Wainwright maintains $75 target on Corbus stockFebruary 11, 2025 | msn.comCorbus Pharmaceuticals' (CRBP) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and issued a $75.00 target price (down previously from $80.00) on shares of Corbus Pharmaceuticals in a research note on Monday.February 10, 2025 | marketbeat.comCorbus Pharmaceuticals (CRBP) Receives a Buy from H.C. WainwrightFebruary 10, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by AnalystsCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given an average rating of "Buy" by the nine ratings firms that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating toFebruary 7, 2025 | marketbeat.comCRBP stock touches 52-week low at $9.26 amid market challengesFebruary 3, 2025 | msn.comPiper Sandler Keeps Their Buy Rating on Corbus Pharmaceuticals (CRBP)February 1, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Short Interest Down 9.1% in JanuaryCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a decline of 9.1% from the December 31st total of 2,650,000 shares. Approximately 22.1% of the company's stock are sold short. Based on an average trading volume of 324,600 shares, the short-interest ratio is currently 7.4 days.February 1, 2025 | marketbeat.comCorbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 28, 2025 | globenewswire.comCRBP stock touches 52-week low at $10.43 amid market fluctuationsJanuary 24, 2025 | msn.comCorbus Pharmaceuticals (NASDAQ:CRBP) Stock, Insider Trading ActivityJanuary 21, 2025 | benzinga.comShort Interest in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Decreases By 9.1%Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 2,410,000 shares, a drop of 9.1% from the December 15th total of 2,650,000 shares. Currently, 22.1% of the company's stock are short sold. Based on an average daily volume of 324,600 shares, the days-to-cover ratio is presently 7.4 days.January 18, 2025 | marketbeat.comCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by BrokeragesCorbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned a consensus recommendation of "Buy" from the nine brokerages that are currently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buJanuary 13, 2025 | marketbeat.comCorbus Pharmaceuticals announes data for CRB-701 from Western Dose studyJanuary 8, 2025 | markets.businessinsider.comCorbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025January 8, 2025 | markets.businessinsider.com Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRBP Media Mentions By Week CRBP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRBP News Sentiment▼0.670.57▲Average Medical News Sentiment CRBP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRBP Articles This Week▼23▲CRBP Articles Average Week Get Corbus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CYRX News CMPS News OLMA News ARCT News AURA News ATAI News GLUE News SEPN News PVLA News ATYR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRBP) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corbus Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corbus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRBP Stock Free CRBP Stock Alerts